Subgroup Analyses in RRMM Patients Receiving Real-Life Standard of Care in the LocoMMotion Study (https://www.myeloma.org/videos/subgroup-analyses-rrmm-patients-receiving-real-life-standard-care-locommotion-study)
Subgroup Analyses in RRMM Patients Receiving Real-Life SOC in the LocoMMotion Study at EHA 2022
Dr. Hermann Einsele Discusses the Subgroup Analyses in RRMM Patients Receiving Real-Life SOC in the LocoMMotion Study at the 2022 European Hematology Association (EHA) Congress.
Abstract title:
Subgroup analyses in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study.
In this video:
Dr. Hermann Einsele (University of Würzburg—Würzburg, Germany) discusses subgroup analyses in RRMM patients receiving real-life standard of care (SOC) in the LocoMMotion Study presented at the 2022 EHA Congress.
What is the purpose of this trial?
The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).
RRMM patients who are triple-class exposed (proteasome inhibitor [PI], immunomodulatory drug [IMiD], and anti-CD38 monoclonal antibody [mAb]) have an urgent and currently unmet clinical need.
LocoMMotion is the first prospective multinational study of real-life standard of care (SOC) in triple-class exposed RRMM patients.
Efficacy in subgroups of patients treated with SOC therapies in the LocoMMotion study are presented.
Conclusion:
Subgroup analyses of this first prospective study of real-life SOC treatment (tx) in triple-class exposed patients with RRMM indicate that specific patient and disease characteristics were associated with poor outcomes. Triple-class refractory and non-triple-class refractory patients had poor outcomes, although the latter had longer median progression-free survival (PFS). These findings should be considered when planning bridging strategy for CAR-T therapy.
Clinical trial information: NCT04035226 (https://clinicaltrials.gov/ct2/show/NCT04035226)
Doctor Bio:
Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, is a physician at the Department of Internal Medicine II at the Würzburg University Hospital. Prof. Einsele obtained medical training from the Universities of Tübingen, Manchester, and London. Since 2004, Prof. Einsele has been a doctor of internal medicine at Julius-Maximilians-Universität Würzburg, where he is also the director of the department. Prof. Einsele is the current Vice-President of the University of Würzburg.
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology